Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
暂无分享,去创建一个
A. Isacchi | E. Casale | J. Bischoff | C. Mercurio | A. Vulpetti | M. Ciomei | D. Ballinari | V. Croci | F. Fiorentini | W. Pastori | P. Pevarello | D. Volpi | P. Roussel | M. Brasca | M. Nesi | D. Borghi | R. Amici | P. Orsini | E. Pesenti | M. Varasi | R. Alzani | N. Avanzi | C. Albanese | Raffaella Amici
[1] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[2] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[3] D. M. Andrews,et al. The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. , 2008, Bioorganic & medicinal chemistry letters.
[4] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[5] C. Mercurio,et al. 6‐Substituted Pyrrolo[3,4‐c]pyrazoles: An Improved Class of CDK2 Inhibitors , 2007, ChemMedChem.
[6] Paul J. Smith,et al. Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents , 2006 .
[7] Nader Fotouhi,et al. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. , 2006, Journal of medicinal chemistry.
[8] Anna Vulpetti,et al. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes. , 2005, Current medicinal chemistry. Anti-cancer agents.
[9] D. W. Fry,et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.
[10] Anna Vulpetti,et al. Benzodipyrazoles: a new class of potent CDK2 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[11] Anna Vulpetti,et al. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.
[12] Punit Marathe,et al. N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.
[13] V. Rizzo,et al. A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer. , 2004, Rapid communications in mass spectrometry : RCM.
[14] M. Barbacid,et al. To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.